Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06724900
PHASE1/PHASE2

A Study Assessing KB304 for the Treatment of Wrinkles in Women

Sponsor: Krystal Biotech, Inc.

View on ClinicalTrials.gov

Summary

The aim of this study is to investigate the safety and efficacy of KB304, an investigational gene therapy to correct moderate to severe wrinkles in the décolleté region (V-shaped chest area). KB304 is an investigational gene therapy that delivers functional, full-length human collagen (COL3) and elastin (tropoelastin) to the skin through small injections using the Sponsor's genetically engineered Herpes Simplex Virus (HSV-1) vector. The study is a randomized double-blind study and participants will receive either KB304 (active group) or placebo (inactive group).

Official title: A Phase 1/2 Study of KB304, a Replication-Defective, Non-Integrating Vector Expressing Human Type III Collagen (COL3) and Tropoelastin for the Treatment of Wrinkles

Key Details

Gender

FEMALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

19

Start Date

2024-11-20

Completion Date

2025-08

Last Updated

2025-05-13

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

KB304

Genetically modified herpes simplex type 1 virus

DRUG

0.9% Normal Saline (NS)

Placebo

Locations (1)

Steve Yoelin Medical Associates

Newport Beach, California, United States